BY MARKETWIRE
-
Viking Therapeutics’ weight-loss pill disappoints in phase 2
Eli Lilli and Novo Nordisk have actually formerly offered arise from stage 3 research studies with their tablet variations.
-
Investment economist disappointed in Zealand Pharma financial results
A share buyback could confirm investors’ belief in the significant unfulfilled price potential, according to Nordnet investment economist.
-
Coloplast’ Q3 earnings underperform analyst forecast
Post-tax earnings concerned DKK 805m versus experts’ expectation of DKK 912m– and contrasted to DKK 1,274 m from the very same duration in 2014.
-
Coloplast creates new business units and shuffles management
Nicolai Buhl, that has actually headed the currently inoperative Persistent Treatment department, is leaving the clinical tool firm.
-
Zealand Pharma CEO: Expectations for the obesity market need to be adjusted
” The marketplace has actually been very concentrated on that can accomplish the fastest and biggest weight management,” states the chief executive officer.
-
Investment economist disappointed in Zealand Pharma financial results
A share buyback could confirm investors’ belief in the significant unfulfilled price potential, according to Nordnet investment economist.
-
Vision AI is Transforming Automated Optical Inspection | RoboticsTomorrow
Imaginative and prescient AI is Reworking Computerized Optical Inspection BitFlow and Advantech are teaming up to invent industry-main systems to make stronger quality, decrease atomize, and develop yield WOBURN, MA, AUGUST https://www.roboticstomorrow.com/info/2025/08/18/imaginative and prescient-ai-is-transforming-automatic-optical-inspection/25327/18, 2025 — Within the relentless pursuit for shut to-zero defects per million (DPM), many manufacturers are turning to Industrial Imaginative and
-
Leo Pharma CEO: Phone ringing off the hook since big deals with Gilead and Boehringer
Leo Pharma presently has around DKK 4bn in cash money, prepared to invest ought to the chance emerge.
-
Prelude to Coloplast’s quarterly results: Slight progress expected while US tariffs remain a key issue
Development is especially gotten out of Coloplast’s urology company.
-
Eli Lilly raises list prices for obesity drugs in the UK
Rates will certainly be increased by 170%.